{
    "id": 32654,
    "fullName": "NR3C1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "NR3C1 positive indicates the presence of the NR3C1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2908,
        "geneSymbol": "NR3C1",
        "terms": [
            "NR3C1",
            "GCCR",
            "GCR",
            "GCRST",
            "GR",
            "GRL"
        ]
    },
    "variant": "positive",
    "createDate": "02/26/2020",
    "updateDate": "02/26/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20589,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ORIC-101 treatment did not inhibit tumor growth in a cell line xenograft model of NR3C1-positive ovarian cancer (PMID: 30091920).",
            "molecularProfile": {
                "id": 35252,
                "profileName": "NR3C1 positive"
            },
            "therapy": {
                "id": 8681,
                "therapyName": "ORIC-101",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16044,
                    "pubMedId": 30091920,
                    "title": "Discovery of a Potent and Selective Steroidal Glucocorticoid Receptor Antagonist (ORIC-101).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30091920"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20590,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ORIC-101, Gemzar (gemcitabine) and Paraplatin (carboplatin) combination treatment enhanced inhibition of tumor growth in a cell line xenograft model of NR3C1-positive ovarian cancer (PMID: 30091920).",
            "molecularProfile": {
                "id": 35252,
                "profileName": "NR3C1 positive"
            },
            "therapy": {
                "id": 9407,
                "therapyName": "Carboplatin + Gemcitabine + ORIC-101",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16044,
                    "pubMedId": 30091920,
                    "title": "Discovery of a Potent and Selective Steroidal Glucocorticoid Receptor Antagonist (ORIC-101).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30091920"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 35252,
            "profileName": "NR3C1 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}